Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Clorazepate Dipotassium

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

11 API Suppliers, 7 USDMF, 2 CEP/COS, 1 JDMF, 4 NDC API, 5 Listed Suppliers, $ API Reference Price

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

114 FDF Dossiers, 85 FDA Orange Book, 25 Europe, 3 Canada, 1 South Africa

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 11.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 22.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 3.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 1 DKSH, 5 Faran Shimi Pharmaceutical, 3 Gangwal Healthcare, 2 Actylis, 1 Aeon Procare, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 5 BASF, 3 DFE Pharma, 1 Finar, 5 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 1 Ingredion Pharma Solutions, 3 Kerry, 8 Microlex e.U, 1 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 8 Roquette, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

19 Fillers, Diluents & Binders, 14 Lubricants & Glidants, 13 Disintegrants & Superdisintegrants, 10 Granulation, 10 Direct Compression, 10 Thickeners and Stabilizers, 6 Controlled & Modified Release, 5 Co-Processed Excipients, 5 Coating Systems & Additives, 4 Parenteral, 4 Taste Masking, 3 Emulsifying Agents, 2 Film Formers & Plasticizers, 2 API Stability Enhancers, 2 Rheology Modifiers, 2 Chewable & Orodispersible Aids, 1 Topical, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

3 News #PharmaBuzz

3 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 28 Regulatory FDF Prices

MARKET PLACE

2 APIs

2 APIs

REF. STANDARDS & IMPURITIES

3 EDQM, 1 USP, 1 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
28/03/2025	Sanofi	France	SANOFI SA	4252	CHLORAZEPATE MONOPOTASSIUM	1981-08-10	Inactive	II	N/A
28/03/2025	Cambrex Corporation	U.S.A	CAMBREX PROFARMACO MILANO SRL	4240	CLORAZEPATE DIPOTASSIUM	1981-06-26	Active	II	Complete	2018-09-27	2018-09-21

Clorazepate Dipotassium

Clorazepate Dipotassium

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

11 API Suppliers

7 USDMF

2 CEP/COS

1 JDMF

4 NDC API

5 Listed Suppliers

$ API Reference Price

INTERMEDIATES

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

114 FDF Dossiers

85 FDA Orange Book

25 Europe

3 Canada

1 South Africa

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 11.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 22.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 3.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

1 DKSH

5 Faran Shimi Pharmaceutical

3 Gangwal Healthcare

2 Actylis

1 Aeon Procare

5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

5 BASF

3 DFE Pharma

1 Finar

5 Gangwal Chemicals

1 Ideal Cures Pvt Ltd

1 Ingredion Pharma Solutions

3 Kerry

8 Microlex e.U

1 Pharmatrans-Sanaq

5 Pluviaendo

3 Prachin Chemical

8 Roquette

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

10 Sigachi Industries

3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

19 Fillers, Diluents & Binders

14 Lubricants & Glidants

13 Disintegrants & Superdisintegrants

10 Granulation

10 Direct Compression

10 Thickeners and Stabilizers

6 Controlled & Modified Release

5 Co-Processed Excipients

5 Coating Systems & Additives

4 Parenteral

4 Taste Masking

3 Emulsifying Agents

2 Film Formers & Plasticizers

2 API Stability Enhancers

2 Rheology Modifiers

2 Chewable & Orodispersible Aids

1 Topical

1 Surfactant & Foaming Agents

DIGITAL CONTENT

3 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions

28 Regulatory FDF Prices

MARKET PLACE

2 APIs

REF. STANDARDS & IMPURITIES

3 EDQM

1 USP

TABLET;ORAL - 11.25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - 15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 22.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - 3.75MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - 7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons